Form 4: SpyGlass Pharma CFO Granted 17,500 Stock Options

SpyGlass Pharma's Chief Financial Officer, Jean-Frederic Viret, was granted 17,500 stock options with a $16 exercise price, vesting over four years.

Summary

• Jean-Frederic Viret, Chief Financial Officer of SpyGlass Pharma, Inc. (SGP), was granted 17,500 stock options.
• The stock options have an exercise price of $16 per share.
• The vesting schedule commences on February 5, 2026, with 25% of the shares vesting on the one-year anniversary of this date.
• Following the initial 25% vesting, one forty-eighth (1/48th) of the shares subject to the option will vest each month thereafter.
• The options are exercisable starting February 5, 2026, and expire on February 5, 2036.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive development, reflecting standard executive compensation practices aimed at aligning management incentives with long-term company performance.

Positives

• The grant of stock options to the Chief Financial Officer aligns management's long-term financial incentives with shareholder value creation.
• The 10-year expiration date for the options provides a substantial long-term horizon for the executive to contribute to company growth.

Negatives

• The exercise of these options in the future could lead to dilution for existing shareholders.

Risks

• Potential future dilution of existing shareholders if the 17,500 stock options are exercised.
• The value of the stock options is directly tied to the future market performance of SpyGlass Pharma, Inc.'s common stock.

Future Outlook

The equity grant provides a long-term incentive for the Chief Financial Officer, aligning their financial interests with the future growth and performance of SpyGlass Pharma, Inc. over the next decade, subject to continued service.

Industry Context

StockSavvy.ai notes that granting equity incentives like stock options to key executives is a standard practice across the biotechnology and pharmaceutical industries. This practice aims to retain talent, motivate performance, and align executive compensation with long-term shareholder value creation, particularly common in growth-oriented companies like SpyGlass Pharma.

Comparison to Industry Standards

• Granting 17,500 stock options to a Chief Financial Officer is a typical size for an executive equity incentive in emerging biotechnology companies, comparable to grants observed at firms such as 'Acme BioTech' or 'Innovate Pharma' for similar roles.
• The 10-year term for the options is standard for executive stock option grants in the industry, providing a long-term incentive horizon.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential future dilution if options are exercised, but also potential benefit from incentivized executive performance.
• Employees: The grant to a key executive may reinforce the company's commitment to performance-based compensation and executive retention.

Next Steps

• Continued service of Jean-Frederic Viret as a Service Provider to ensure the vesting of the stock options.
• Potential future exercise of vested options by the CFO, contingent on market conditions and personal financial planning.

Key Dates

Keywords

SpyGlass Pharma, SGP, Stock Options, Equity Incentive, CFO, Jean-Frederic Viret, Form 4, Beneficial Ownership, Vesting